Expression of the immune targets in tumor-infiltrating immunocytes of gestational trophoblastic neoplasia
Pathology and Oncology Research · 2023
DOI: 10.3389/pore.2023.1610918 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathology and Oncology Research, 2023. Verfasst von Hongyan Cheng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, National Clinical Research Centre for Obstetric and Gynecologic Diseases, Peking Union Medical College Hospi…. Hauptthemen laut MEDLINE: Neoplasms, Choriocarcinoma, Gestational Trophoblastic Disease. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Objectives
To evaluate the expression of emerging immune targets in the tumor-infiltrating immunocytes (TIIs) of human gestational trophoblastic neoplasia (GTN) specimens, and to analyze the correlation between the expression patterns and prognosis of GTN patients.
Methods
Between January 2008 and December 2017, patients who were diagnosed histologically with GTN were included in this study. The expression densities of LAG-3, TIM-3, GAL-9, PD-1, CD68, CD8, and FOXP3 in the TIIs were assessed independently by two pathologists blinded to clinical outcomes. The expression patterns and correlation with patient outcomes were analyzed to identify prognostic factors.
Results
We identified 108 patients with GTN, including 67 with choriocarcinoma, 32 with placental site trophoblastic tumor (PSTT), and 9 with epithelioid trophoblastic tumor (ETT). Almost all GTN patients showed expression of GAL-9, TIM-3, and PD-1 in TIIs (100%, 92.6%, and 90.7%, respectively); LAG-3 was expressed in 77.8% of the samples. The expression densities of CD68 and GAL-9 were significantly higher in choriocarcinoma than that in PSTT and ETT. The TIM-3 expression density in choriocarcinoma was higher than that in PSTT. In addition, the expression density of LAG-3 in the TIIs of choriocarcinoma and PSTT was higher than that in ETT. There was no statistical difference in the expression pattern of PD-1 among different pathological subtypes. The positive expression of LAG-3 in tumor TIIs was a prognostic factor for disease recurrence, and patients with positive expression of LAG-3 in the TIIs had poorer disease-free survival ( p = 0.026).
Conclusion
Our study evaluated the expression of immune targets PD-1, TIM-3, LAG-3, and GAL-9 in the TIIs of GTN patients and found that they were widely expressed but not associated with patients’ prognoses, excepting the positive expression of LAG-3 was a prognostic factor for disease recurrence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, National Clinical Research Centre for Obstetric and Gynecologic Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical Coll…
- Department of Pathology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Cheng, H., Zong, L., Yu, S., Chen, J., Wan, X., Xiang, Y., & Yang, J. (2023). Expression of the immune targets in tumor-infiltrating immunocytes of gestational trophoblastic neoplasia. Pathology and Oncology Research. https://doi.org/10.3389/pore.2023.1610918
Vancouver
Cheng H, Zong L, Yu S, Chen J, Wan X, Xiang Y, et al. Expression of the immune targets in tumor-infiltrating immunocytes of gestational trophoblastic neoplasia. Pathology and Oncology Research. 2023. doi:10.3389/pore.2023.1610918
BibTeX
@article{Cheng2023,
author = {Cheng, Hongyan and Zong, Liju and Yu, Shuangni and Chen, Jie and Wan, Xirun and Xiang, Yang and Yang, Junjun},
title = {Expression of the immune targets in tumor-infiltrating immunocytes of gestational trophoblastic neoplasia},
journal = {Pathology and Oncology Research},
year = {2023},
doi = {10.3389/pore.2023.1610918}
}
EUVIMED